• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24905 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Local hyperbaric oxygen therapy for diabetic foot ulcers]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP "Chronic obstructive pulmonary disease (COPD)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Test quality: Evidence report for the S3 guideline on allergic rhinitis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [House dust mites: Evidence report for the S3 guideline on allergic rhinitis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pollen: Evidence report for the S3 guideline on allergic rhinitis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pets-rodents: Evidence report for the S3 guideline on allergic rhinitis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Flour: Evidence report for the S3 guideline on allergic rhinitis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Laboratory animals – farm animals: Evidence report for the S3 guideline on allergic rhinitis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of pelvic floor training during pregnancy for the prevention of pre and postnatal urinary incontinence]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy and safety of model-informed precision dosing of biologic agents]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Neurosurgical robot for electrode implantation, brain biopsies and spinal surgery]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Artificial intelligence software to detect viable tissue in stroke patients on CT or perfusion MRI of the skull]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Telemedicine for the follow-up of post-stroke patients]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, clinical and cost-effectiveness of neonatal screening for type 1 citrullinaemia, trifunctional protein deficiency, holocarboxyl synthetase deficiency, argininosuccinic aciduria and 3-methylcrotonyl-CoA carboxylase deficiency]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Safety, clinical effectiveness and cost-effectiveness of neonatal screening for Pompe disease]
2026     Belgian Health Care Knowledge Centre (KCE) Assessment of a mobile application in the rehabilitation of patients undergoing primary knee or hip arthroplasty (Study 2020-01)
2026     Belgian Health Care Knowledge Centre (KCE) Economic evaluation based on ‘PRECISe’, a randomised clinical trial funded by the KCE Trials programme (Study 2024-92)
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Barriers and facilitators when implementing guidelines in health and social care for the elderly]
2026     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Nirmatrelvir plus ritonavir (Paxlovid)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the lower age limit and frequency of early-detection colonoscopy in the colorectal cancer screening programme]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acupuncture for migraine prophylaxis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Newborn screening for metachromatic leukodystrophy]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Development of a decision aid for carotid revascularization surgery for carotid stenosis]
2026     Swiss Federal Office of Public Health (FOPH) Valerian extracts for sleep disorders, anxiety or restlessness
2026     Swiss Federal Office of Public Health (FOPH) Ginkgo biloba in patients with decreasing mental performance, peripheral arterial occlusive disease, vertigo or tinnitus
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of the regulations governing a tiered system of emergency structures in hospitals]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for prostate cancer]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Radiofrequency energy treatment for organic erectile dysfunction]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Lattice radiotherapy in the curative or palliative treatment of deep, large-volume tumors and metastatic or unresectable disease]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [X-ray image of the lung: Can artificial intelligence support the analysis of X-ray images?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quality of sleep: Can taking melatonin as a dietary supplement, e.g. in the form of tablets, sprays or soft gums, help to improve sleep?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vulvodynia (itching and pain in the vulva area): What non-drug treatment options are promising?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Adhesions in the abdominal cavity: Do other measures help to relieve symptoms instead of surgery?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Revision of the information materials on colorectal cancer screening]
2026     Swiss Federal Office of Public Health (FOPH) Thermoablation for benign thyroid nodules
2026     Swiss Federal Office of Public Health (FOPH) Injection therapies with corticosteroids for chronic tendinopathy or enthesopathy
2026     Swiss Federal Office of Public Health (FOPH) Superficial/deep heat in physiotherapy for musculoskeletal conditions
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Reinforced foster homes]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficacy and safety of emotional freedom techniques for the treatment of anxiety, depression and post traumatic stress disorders]
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of technologies for the assessment of attention deficit hyperactivity disorder: a systematic review and economic model
2025     Scottish Health Technologies Group (SHTG) Digital prevention programmes for people at risk of developing type 2 diabetes
2025     Scottish Health Technologies Group (SHTG) Electrocardiogram (ECG) patch monitors for the detection of cardiac rhythm abnormalities
2025     Scottish Health Technologies Group (SHTG) Home blood pressure monitoring for people with suspected or confirmed hypertension
2025     Canary Health Service [Effectiveness, safety and cost-effectiveness of neonatal screening for familial hypercholesterolemia]
2025     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Therapeutic use of blankets, vests and other weighted objects with different clienteles]
2025     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Effectiveness of mental health outreach services for adolescent clientele: modalities and approaches in a context of scarce resources]
2025     Haute Autorite de sante (HAS) [Appropriateness of prescribing erythrocyte sedimentation rate (ESR) – are there any remaining?]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Hybrid operating rooms]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirdametinib (neurofibromatosis type 1) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Agency for Care Effectiveness (ACE) Hydrogel rectal spacers for rectum protection during radiation therapy for prostate cancer
2025     Agency for Care Effectiveness (ACE) Advanced hybrid closed loop system for people with type 1 diabetes mellitus
2025     Agency for Care Effectiveness (ACE) Intraoperative cell salvage for surgeries with anticipated or possible significant blood loss
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (urothelial carcinoma) – Addendum to Project A25-97]
2025     Agency for Care Effectiveness (ACE) Phagenyx to improve swallowing in severe post-stroke dysphagia
2025     Agency for Care Effectiveness (ACE) Biomarker-based brain trauma assessment tests to aid in the evaluation of mild traumatic brain injury in adults
2025     Agency for Care Effectiveness (ACE) Portable Neuromodulation Stimulator (PoNS) for treating gait deficit due to multiple sclerosis
2025     Agency for Care Effectiveness (ACE) LumiSystem for intraoperative tumour margin assessment following breast-conserving surgery
2025     Agency for Care Effectiveness (ACE) Edison Histotripsy System for non-invasive destruction of liver tumours
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Securing scientific research without PubMed and ClinicalTrials.gov]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sepiapterin (phenylketonuria) – Addendum to Project G25-23]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (gastric or gastroesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linvoseltamab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (nasopharyngeal carcinoma) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (small cell lung cancer, extensive stage) – Benefit assessment according to §35a Social Code Book V]
2025     Basque Office for Health Technology Assessment (OSTEBA) [CT-guided percutaneous ablation for lung metastasis using radiofrequency or microwaves in patients who are not eligible for curative local and/ or systemic treatment]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Magnetic nanoparticles and a magnetic field generator for inducing hyperthermia in the treatment of pancreatic cancer]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Efficacy and safety of non-invasive brain stimulation therapies for the neurorehabilitation of patients with stroke]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of children with peritoneal carcinomatosis]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Effectiveness and safety of adaptive radiation therapy in patients with lymphoma, head and neck cancer or lung carcinoma]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Intrasaccular device for endovascular treatment of cerebral aneurysm]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Intraoperative fluorescence imaging for cancer cell identification]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Cardiovascular monitoring systems using photoplethysmography]
2025     Basque Office for Health Technology Assessment (OSTEBA) [Intestinal ultrasound in inflammatory bowel disease: diagnostic effectiveness, cost-effectiveness and patient and health professional perspectives]
2025     Basque Office for Health Technology Assessment (OSTEBA) [3D printing in traumatology, cardiology, vascular surgery, maxillofacial surgery, neurosurgery, joint injuries, and bone repair]
2025     Agenzia nazionale per i servizi sanitari regionali (Agenas) Robotic surgery systems in general surgery, gynecology, and urology
2025     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of extending population-based breast cancer screening to women aged 45–49 and 70–74 and the use of digital breast tomosynthesis in screening women with dense breast tissue]
2025     National Institute for Health and Care Excellence (NICE) Slide sheets for moving or repositioning a person: late-stage assessment. NICE HealthTech guidance 745
2025     National Institute for Health and Care Excellence (NICE) Drug-eluting stents for treating coronary artery disease: late-stage assessment. NICE HealthTech guidance 747
2025     National Institute for Health and Care Excellence (NICE) Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment. NICE HealthTech guidance 751
2025     National Institute for Health and Care Excellence (NICE) Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessment. NICE HealthTech guidance 753
2025     National Institute for Health and Care Excellence (NICE) One-piece closed bags for colostomies: late-stage assessment. NICE HealthTech guidance 754
2025     National Institute for Health and Care Excellence (NICE) Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: late-stage assessment. NICE HealthTech guidance 757
2025     National Institute for Health and Care Excellence (NICE) Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment. NICE HealthTech guidance 759
2025     National Institute for Health and Care Excellence (NICE) Compression products for treating venous leg ulcers: late-stage assessment. NICE HealthTech guidance 758
2025     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment. NICE HealthTech guidance 739
2025     National Institute for Health and Care Excellence (NICE) Robot-assisted surgery for orthopaedic procedures: early value assessment. NICE HealthTech guidance 743
2025     National Institute for Health and Care Excellence (NICE) Robot-assisted surgery for soft tissue procedures: early value assessment. NICE HealthTech guidance 742
2025     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment. NICE HealthTech guidance 746
2025     National Institute for Health and Care Excellence (NICE) Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment. NICE HealthTech guidance 748
2025     National Institute for Health and Care Excellence (NICE) Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessment. NICE HealthTech guidance 756
2025     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessment. NICE HealthTech guidance 760
2025     National Institute for Health and Care Excellence (NICE) Digital platforms to support cardiac rehabilitation: early value assessment. NICE HealthTech guidance 761
2025     Scottish Health Technologies Group (SHTG) Esaote® extremity MRI scanners
2025     Agency of Health Technology Assessment of Uruguay (AETSU) [iSGLT2 in the treatment of chronic kidney disease]
2025     Agency of Health Technology Assessment of Uruguay (AETSU) [iSGLT2 in the treatment of heart failure]